Latest news with #DTIL
Business Upturn
7 days ago
- Business
- Business Upturn
Eureka Forbes Limited enhances its manufacturing capability with a strategic partnership with Dixon Technologies India Limited
Eureka Forbes Limited, one of India's leading health and hygiene brands, is proud to announce its strategic partnership with Dixon Technologies (India) Limited (DTIL), a leader in electronic manufacturing services (EMS). Business Wire India Eureka Forbes Limited, one of India's leading health and hygiene brands, is proud to announce its strategic partnership with Dixon Technologies (India) Limited (DTIL), a leader in electronic manufacturing services (EMS). This collaboration marks an important step in expanding Eureka Forbes' Vacuum Cleaner port f olio by assembly/manufacture & supply of robotic vacuum cleaners, reinforcing its position as a trusted name in Indian households. Under this partnership, DTIL will produce a range of Robotic Vacuum Cleaners for Eureka Forbes leveraging its cutting-edge facilities and extensive manufacturing expertise. Dixon's ISO-certified plants will ensure that the Eureka Forbes robotic vacuum cleaners meet rigorous standards of durability, quality, and innovation. This collaboration aligns with Eureka Forbes' vision of delivering value-driven, high-performing, health-tech products that cater to the evolving needs of Indian consumers. Talking about the partnership, Mr. Pratik Pota, MD & CEO, Eureka Forbes Ltd., said, 'At Eureka Forbes, we are committed to delivering innovative, high-performing products that enrich the lives of our consumers. Our strategic partnership with Dixon Technologies is a testament to this commitment and a significant step towards strengthening our Make in India vision. By combining Eureka Forbes's deep consumer insight and innovation prowess with Dixon's manufacturing excellence, we aim to accelerate our presence in the robotic vacuum cleaner category and bring cutting-edge, locally made solutions to Indian homes.' Mr. Atul B. Lall, Vice Chairman and Managing Director, Dixon Technologies (India), added , 'We are pleased to formalize our strategic partnership with Eureka Forbes, a brand synonymous with trust and innovation in home appliances segment. This agreement marks a significant milestone for our company as we expand our capabilities in the homecare segment. By combining our advanced manufacturing expertise with Eureka Forbes's deep market understanding and product leadership, we aim to deliver high-quality vacuum cleaners that meet the evolving needs of consumers and market. We see this as the beginning of a long-term association that will drive value for both organizations and ultimately benefit customers across markets.' Dixon Technologies (India) Limited is the largest home grown design-focused and solutions company engaged in manufacturing products in the consumer durables, lighting and mobile phones markets in India. Their diversified product port f olio includes (i) Consumer electronics like LED TVs; (ii) Home appliances like washing machines; (iii) Lighting products like LED bulbs and tube lights, down lighters; (iv) Mobile phones; and (v) Wearables and Hearables(vi) Refrigerators (vii) Telecom and IT Hardware products. Dixon also provides solutions in reverse logistics i.e., repair and refurbishment services of LED TV panels. The company is renowned for its high-quality standards, ethical business practices and commitment, making it a preferred partner across various industry verticals. Through this collaboration, Eureka Forbes aims to further elevate its product offerings, strengthen its presence in the robotic vacuum market, and continue its mission to become a household name across India. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Business Standard
07-07-2025
- Business
- Business Standard
Eureka Forbes partners with Dixon Technologies
Dixon Technologies to produce a range of vacuum cleaners for Eureka Forbes Eureka Forbes (Eureka) announced its strategic partnership with Dixon Technologies (India) (DTIL), a leader in electronic manufacturing services (EMS). This collaboration marks an important step in expanding Eureka's vacuum cleaners portfolio by assembly/manufacture & supply of robotic vacuum cleaners, reinforcing its position as a trusted name in Indian households. Under this partnership, DTIL will produce a range of robotic vacuum cleaners for Eureka leveraging its cutting-edge facilities and extensive manufacturing expertise. DTIL's ISO certified plants will ensure that Eureka's robotic vacuum cleaners meets rigorous standards of durability, quality, and innovation. This collaboration aligns with Eureka's vision of delivering value-driven, high-performing products that cater to the evolving needs of Indian consumers.
Yahoo
15-05-2025
- Business
- Yahoo
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -413.95%. A quarter ago, it was expected that this genome editing company would post a loss of $0.42 per share when it actually produced a loss of $3.20, delivering a surprise of -661.90%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Precision BioSciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 99.71%. This compares to year-ago revenues of $17.58 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Precision BioSciences shares have added about 29.9% since the beginning of the year versus the S&P 500's gain of 0.2%. While Precision BioSciences has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Precision BioSciences: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $13.7 million in revenues for the coming quarter and -$1.17 on $45.6 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Fortress Biotech (FBIO), another stock in the same industry, has yet to report results for the quarter ended March 2025. This biopharmaceutical company is expected to post quarterly loss of $0.44 per share in its upcoming report, which represents a year-over-year change of +57.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Fortress Biotech's revenues are expected to be $10.3 million, down 21% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report Fortress Biotech, Inc. (FBIO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
15-05-2025
- Business
- Yahoo
Precision BioSciences: Q1 Earnings Snapshot
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based company said it had a loss of $2.21. The genome editing company posted revenue of $29,000 in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on DTIL at Sign in to access your portfolio
Business Wire
08-05-2025
- Business
- Business Wire
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that it will publish financial results for the first quarter 2025 and provide a business update on May 15, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS ® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit The ARCUS ® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
